Jamie Spaeth - Lantheus Holdings Chief Officer
Executive
Jamie Spaeth is Chief Officer of Lantheus Holdings
| Phone | 978 671 8001 |
| Web | https://www.lantheus.com |
Lantheus Holdings Management Efficiency
The company has return on total asset (ROA) of 0.1535 % which means that it generated a profit of $0.1535 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.3282 %, meaning that it created $0.3282 on every $100 dollars invested by stockholders. Lantheus Holdings' management efficiency ratios could be used to measure how well Lantheus Holdings manages its routine affairs as well as how well it operates its assets and liabilities. As of now, Lantheus Holdings' Return On Tangible Assets are increasing as compared to previous years. The Lantheus Holdings' current Return On Capital Employed is estimated to increase to 0.28, while Return On Equity is projected to decrease to 0.27. As of now, Lantheus Holdings' Return On Tangible Assets are increasing as compared to previous years. The Lantheus Holdings' current Intangibles To Total Assets is estimated to increase to 0.16, while Non Current Assets Total are projected to decrease to under 403.2 M.Lantheus Holdings currently holds 974 K in liabilities with Debt to Equity (D/E) ratio of 0.33, which is about average as compared to similar companies. Lantheus Holdings has a current ratio of 1.81, which is within standard range for the sector. Note, when we think about Lantheus Holdings' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Krishna MS | Dr Reddys Laboratories | 52 | |
| Sandeep Poddar | Dr Reddys Laboratories | N/A | |
| YUGANDHAR PUVVALA | Dr Reddys Laboratories | 48 | |
| Dan MBA | Amphastar P | N/A | |
| Jenny Steingrimsdottir | Alvotech Warrant | N/A | |
| SANJAY SHARMA | Dr Reddys Laboratories | 52 | |
| Matthew CPA | Neurocrine Biosciences | 44 | |
| Darin Esq | Neurocrine Biosciences | 59 | |
| Mannam Venkatanarasimham | Dr Reddys Laboratories | N/A | |
| Kyle Gano | Neurocrine Biosciences | 52 | |
| Raymond Vre | Dr Reddys Laboratories | 52 | |
| Julie Cooke | Neurocrine Biosciences | 59 | |
| Vivek Mittal | Dr Reddys Laboratories | N/A | |
| Dimitri Grigoriadis | Neurocrine Biosciences | 66 | |
| MP MBA | Amphastar P | N/A | |
| Richa Periwal | Dr Reddys Laboratories | N/A | |
| MBA MPH | Amphastar P | N/A | |
| Archana Bhaskar | Dr Reddys Laboratories | 53 | |
| Eva Gunnlaugsdottir | Alvotech Warrant | N/A | |
| Anil Namboodiripad | Dr Reddys Laboratories | 54 | |
| Christopher OBrien | Neurocrine Biosciences | 67 | |
Management Performance
| Return On Equity | 0.33 | ||||
| Return On Asset | 0.15 |
Lantheus Holdings Leadership Team
Elected by the shareholders, the Lantheus Holdings' board of directors comprises two types of representatives: Lantheus Holdings inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lantheus. The board's role is to monitor Lantheus Holdings' management team and ensure that shareholders' interests are well served. Lantheus Holdings' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lantheus Holdings' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lee Howe, Chief Officer | ||
| Daniel Niedzwiecki, General Officer | ||
| Dorothy Barr, Senior Operations | ||
| Paul Blanchfield, Chief Officer | ||
| Amanda Morgan, Senior Commercial | ||
| Etienne Montagut, Senior Vice President - Corporate Development | ||
| Carol Walker, Vice President | ||
| Brian Markison, Non-Executive Independent Chairman | ||
| Mark Kinarney, Director Relations | ||
| CFA Marshall, Chief Officer | ||
| Jamie Spaeth, Chief Officer | ||
| Melissa Downs, Director Communications | ||
| Linda Lennox, VP Staff | ||
| Mary Heino, CEO and President and Director | ||
| JeanClaude MD, Chief Officer | ||
| Andrea Sabens, Chief Officer | ||
| Kimberly Brown, Chief Officer |
Lantheus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lantheus Holdings a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.33 | ||||
| Return On Asset | 0.15 | ||||
| Profit Margin | 0.20 % | ||||
| Operating Margin | 0.28 % | ||||
| Current Valuation | 6.78 B | ||||
| Shares Outstanding | 68.48 M | ||||
| Shares Owned By Insiders | 2.74 % | ||||
| Shares Owned By Institutions | 97.26 % | ||||
| Number Of Shares Shorted | 7.31 M | ||||
| Price To Earning | 36.43 X |
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Other Tools for Lantheus Stock
When running Lantheus Holdings' price analysis, check to measure Lantheus Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lantheus Holdings is operating at the current time. Most of Lantheus Holdings' value examination focuses on studying past and present price action to predict the probability of Lantheus Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lantheus Holdings' price. Additionally, you may evaluate how the addition of Lantheus Holdings to your portfolios can decrease your overall portfolio volatility.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |